Department of Physical Therapy, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, California, USA.
Disabil Rehabil. 2011;33(25-26):2596-604. doi: 10.3109/09638288.2011.582925. Epub 2011 Jun 20.
To determine the validity and reliability of Short Form 36 Version 2 (SF36v2) in sub-groups of individuals with fatigue.
Thirty subjects participated in this study, including n = 16 subjects who met case definition criteria for chronic fatigue syndrome (CFS) and n = 14 non-disabled sedentary matched control subjects. SF36v2 and Multidimensional Fatigue Inventory (MFI-20) were administered before two maximal cardiopulmonary exercise tests (CPETs) administered 24 h apart and an open-ended recovery questionnaire was administered 7 days after CPET challenge. The main outcome measures were self-reported time to recover to pre-challenge functional and symptom status, frequency of post-exertional symptoms and SF36v2 sub-scale scores.
Individuals with CFS demonstrated significantly lower SF36v2 and MFI-20 sub-scale scores prior to CPET. Between-group differences remained significant post-CPET, however, there were no significant group by test interaction effects. Subjects with CFS reported significantly more total symptoms (p < 0.001), as well as reports of fatigue (p < 0.001), neuroendocrine (p < 0.001), immune (p < 0.01), pain (p < 0.01) and sleep disturbance (p < 0.01) symptoms than control subjects as a result of CPET. Many symptom counts demonstrated significant relationships with SF36v2 sub-scale scores (p < 0.05). SF36v2 and MFI-20 sub-scale scores demonstrated significant correlations (p < 0.05). Various SF36v2 sub-scale scores demonstrated significant predictive validity to identify subjects who recovered from CPET challenge within 1 day and 7 days (p < 0.05). Potential floor effects were observed for both questionnaires for individuals with CFS.
Various sub-scales of SF36v2 demonstrated adequate reliability and validity for clinical and research applications. Adequacy of sensitivity to change of SF36v2 as a result of a fatiguing stressor should be the subject of additional study.
确定短式 36 版本 2（SF36v2）在疲劳亚组人群中的有效性和可靠性。
30 名受试者参与了这项研究，包括 n = 16 名符合慢性疲劳综合征（CFS）病例定义标准的受试者和 n = 14 名非残疾久坐匹配对照组受试者。在两次相隔 24 小时的最大心肺运动测试（CPET）前和 CPET 挑战后 7 天进行开放式恢复问卷时，受试者接受了 SF36v2 和多维疲劳量表（MFI-20）的测试。主要的观察指标是自我报告的恢复到挑战前的功能和症状状态的时间、运动后症状的频率和 SF36v2 子量表评分。
在进行 CPET 之前，CFS 患者的 SF36v2 和 MFI-20 子量表评分明显较低。CPET 后两组之间的差异仍然显著，但没有显著的组间测试交互作用。CFS 患者报告的总症状明显更多（p < 0.001），以及疲劳（p < 0.001）、神经内分泌（p < 0.001）、免疫（p < 0.01）、疼痛（p < 0.01）和睡眠障碍（p < 0.01）症状也比对照组多，这是由于 CPET 引起的。许多症状计数与 SF36v2 子量表评分显著相关（p < 0.05）。SF36v2 和 MFI-20 子量表评分显著相关（p < 0.05）。各种 SF36v2 子量表评分对识别在 1 天和 7 天内从 CPET 挑战中恢复的受试者具有显著的预测有效性（p < 0.05）。对于 CFS 患者，两个问卷都观察到了潜在的地板效应。
SF36v2 的各种子量表具有足够的可靠性和有效性，适用于临床和研究应用。SF36v2 作为疲劳应激源的变化敏感性的充分性应该是进一步研究的主题。
